Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The agreement grants Zentiva commercialisation rights outside the US and Canada, primarily in Europe and CIS markets. Lupin will receive up to USD 50 million in milestone payments.